<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">NIMODIPINE</span><br/>(ni-mo'di-peen)<br/><span class="topboxtradename">Nimotop<br/></span><b>Classifications:</b> <span class="classification">cardiovascular agent</span>; <span class="classification">calcium channel blocker</span><br/><b>Prototype: </b>Nifedipine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>30 mg capsule</p>
<h1><a name="action">Actions</a></h1>
<p>Calcium channel blocking agent that is relatively selective for cerebral arteries compared with arteries elsewhere in the
         body. This may be attributed to the drug's high lipid solubility and specific binding to cerebral tissue.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Reduces vascular spasms in cerebral arteries during a stroke.</p>
<h1><a name="uses">Uses</a></h1>
<p>To improve neurologic deficits due to spasm following subarachnoid hemorrhage from ruptured congenital intracranial aneurysms
         in patients who are in good neurologic condition posticus (e.g., Hunt and Hess Grades IIII).
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Migraine headaches, ischemic seizures.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>None known.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Hepatic impairment; pregnancy (category C), and lactation. Safety and effectiveness in children are not established.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Subarachnoid Hemorrhage</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 60 mg q4h for 21 d, start therapy within 96 h of subarachnoid hemorrhage<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Make a hole in both ends of the capsule with an 18-gauge needle and extract the contents into a syringe if patient is unable
            to swallow. Empty the contents into an enteral (if in use) tube and wash down with 30 mL of NS.
         </li>
<li>Store below 40° C (104° F); protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache. <span class="typehead">CV:</span> <span class="speceff-common">Hypotension.</span> <span class="typehead">GI:</span> Hemorrhage, mild, transient increase in liver function tests. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Hypotensive effects may be increased when nimodipine is combined with other <span class="classification">calcium channel blockers</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract; approximately 13% reaches systemic circulation (first pass metabolism). <span class="typehead">Peak:</span> 1 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier; possibly crosses placenta; distributed into breast milk. <span class="typehead">Metabolism:</span> 85% metabolized in liver; 15% metabolized in kidneys. <span class="typehead">Elimination:</span> &gt;50% excreted in urine, 32% in feces. <span class="typehead">Half-Life:</span> 89 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Take apical pulse prior to administering drug and hold it if pulse is below 60. Notify the physician.</li>
<li>Establish baseline data before treatment is started: BP, pulse, and laboratory evaluations of liver and kidney function.</li>
<li>Monitor frequently for adverse drug effects, including hypotension, peripheral edema, tachycardia, or skin rash.</li>
<li>Monitor frequently for dizziness or lightheadedness in older adult patients; risk of hypotension is increased.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report gradual weight gain and evidence of edema (e.g., tight rings on fingers, ankle swelling).</li>
<li>Keep follow-up appointments for monitoring of progress during therapy.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>